OM:SUS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Surgical Science Sweden

Executive Summary

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training.


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Surgical Science Sweden's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SUS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.3%

SUS

0.7%

SE Medical Equipment

2.6%

SE Market


1 Year Return

32.0%

SUS

17.0%

SE Medical Equipment

18.1%

SE Market

Return vs Industry: SUS exceeded the Swedish Medical Equipment industry which returned 15.9% over the past year.

Return vs Market: SUS exceeded the Swedish Market which returned 16.9% over the past year.


Shareholder returns

SUSIndustryMarket
7 Day-1.3%0.7%2.6%
30 Day-1.8%9.9%5.1%
90 Day34.9%14.2%20.9%
1 Year32.0%32.0%18.8%17.0%20.0%18.1%
3 Year514.8%514.8%86.8%65.3%32.5%18.5%
5 Yearn/a78.4%45.0%45.4%16.6%

Price Volatility Vs. Market

How volatile is Surgical Science Sweden's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Surgical Science Sweden undervalued compared to its fair value and its price relative to the market?

135.32x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SUS (SEK75) is trading above our estimate of fair value (SEK63.1)

Significantly Below Fair Value: SUS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SUS is poor value based on its PE Ratio (135.3x) compared to the SE Medical Equipment industry average (56.9x).

PE vs Market: SUS is poor value based on its PE Ratio (135.3x) compared to the Swedish market (22.1x).


Price to Earnings Growth Ratio

PEG Ratio: SUS is poor value based on its PEG Ratio (3.1x)


Price to Book Ratio

PB vs Industry: SUS is overvalued based on its PB Ratio (6.3x) compared to the SE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Surgical Science Sweden forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

43.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUS's forecast earnings growth (43% per year) is above the savings rate (0.5%).

Earnings vs Market: SUS's earnings (43% per year) are forecast to grow faster than the Swedish market (19.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SUS's revenue (26.2% per year) is forecast to grow faster than the Swedish market (6.4% per year).

High Growth Revenue: SUS's revenue (26.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SUS's Return on Equity is forecast to be low in 3 years time (9.8%).


Next Steps

  • Explore growth companies in the Healthcare industry.

Past Performance

How has Surgical Science Sweden performed over the past 5 years?

24.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SUS has high quality earnings.

Growing Profit Margin: SUS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SUS has become profitable over the past 5 years, growing earnings by 24.2% per year.

Accelerating Growth: SUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (19.3%).


Return on Equity

High ROE: SUS's Return on Equity (4.2%) is considered low.


Next Steps

Financial Health

How is Surgical Science Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: SUS's short term assets (SEK116.4M) exceed its short term liabilities (SEK37.3M).

Long Term Liabilities: SUS's short term assets (SEK116.4M) exceed its long term liabilities (SEK14.0M).


Debt to Equity History and Analysis

Debt Level: SUS is debt free.

Reducing Debt: SUS has no debt compared to 5 years ago when its debt to equity ratio was 10.7%.

Debt Coverage: SUS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SUS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Surgical Science Sweden current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SUS's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Gisli Hennermark (48 yo)

5.58yrs

Tenure

Mr. Gisli Hennermark serves as Chief Executive Officer of Surgical Science Sweden AB (publ) since 2015. He received MSc from Stockholm School of Economics and Cornell University. He worked previously as a ...


Leadership Team

NamePositionTenureCompensationOwnership
Gisli Hennermark
Chief Executive Officer5.58yrsno data1.05%
SEK 27.2m
Anna Ahlberg
Chief Financial Officer2.58yrsno data0.065%
SEK 1.7m
Anders Larsson
Co-Founder & CTO0.58yrno data0.14%
SEK 3.6m
Anders Melander
Director of Global Sales5.58yrsno data0.058%
SEK 1.5m
Hans Uddenberg
Market Director0.58yrno data0.029%
SEK 750.0k
Tommy Forsell
Head of Business Area Industry/OEM & Director1.58yrsno data10.11%
SEK 261.6m
Daniel Evestedt
Head of Development0.75yrno data10.11%
SEK 261.6m

0.8yrs

Average Tenure

48yo

Average Age

Experienced Management: SUS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Tommy Forsell
Head of Business Area Industry/OEM & Director1.58yrsno data10.11%
SEK 261.6m
Roland Bengtsson
Chairman of the Board3.58yrsno data18.67%
SEK 482.9m
Jan Bengtsson
Director15.58yrsno data24.39%
SEK 631.1m
Thomas Eklund
Director3.58yrsno data0.0029%
SEK 75.0k
Nils Sellbom
Director8.58yrsno data0.049%
SEK 1.3m

3.6yrs

Average Tenure

65yo

Average Age

Experienced Board: SUS's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.


Top Shareholders

Company Information

Surgical Science Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Surgical Science Sweden AB (publ)
  • Ticker: SUS
  • Exchange: OM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr2.587b
  • Shares outstanding: 34.49m
  • Website: https://www.surgicalscience.com

Location

  • Surgical Science Sweden AB (publ)
  • Drakegatan 7 A, 3 tr.
  • Gothenburg
  • Västra Götaland County
  • 412 50
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SUSOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017

Biography

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/11 21:49
End of Day Share Price2020/08/11 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.